Dr Reddy's Labs acquires entire MenoLabs supplements portfolio
Brands include MenoFit and MenoGlow probiotics, Happy Fiber and Well Rested dietary supplements, Athena's Shield menopause support supplement, and Goodness Glow and Keep Glowing Gorgeous supplements for healthy aging support.
Hyderabad: Dr Reddy's Laboratories Ltd. has announced that it has acquired MenoLabs business, a women’s health and dietary supplement branded portfolio from Amyris, Inc. in Amyris’ Chapter 11 sales process.
Dr. Reddy’s acquired the entire MenoLabs supplements portfolio which includes seven branded products designed to provide health support and address symptoms of perimenopause and menopause.
Brands include MenoFit and MenoGlow probiotics, Happy Fiber and Well Rested dietary supplements, Athena’s Shield menopause support supplement, and Goodness Glow and Keep Glowing Gorgeous supplements for healthy aging support.
The deal also includes the MenoLife health tracker app which supports the product line and provides community, education, and information to consumers regarding menopause.
MenoLabs portfolio of products is sold in the United States, primarily through the brand’s own and other e-commerce marketplaces including Amazon and Walmart.
“The MenoLabs acquisition will serve as a catalyst to accelerate growth in this space and build upon our aspiration to lead in the fast-growing women’s nutritional and wellness markets,” says Marc Kikuchi, Chief Executive Officer for Dr. Reddy’s in North America. “The acquisition complements Dr Reddy’s U.S. selfcare and wellness business portfolio of brands and addresses unmet needs of consumers for sciencebased, research-driven products that provide relief from the symptoms of menopause. For these and many other reasons, I believe we are well-positioned to successfully integrate and grow the business.”
Read also: Dr Reddys Labs arm, Coya Therapeutics ink pact for Amyotrophic Lateral Sclerosis therapy COYA 302
Established in 1984, Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. The Company offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy's major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe.
Next Story
